Evaluating Inflammation for Cardiometabolic Risk
Speakers
Dr. Trisha Winchester, PhD, MBA
Sign up for Academy to watch
Gain access to evolving research into evidence-based education that supports streamlined whole person care.
About this webinar
Routine lipid screening plays an important role in cardiovascular risk assessment, but it may not adequately identify risk of adverse events. In fact, nearly 50% of all heart attacks and strokes occur in patients who had “normal” cholesterol levels. Evidence suggests that inflammation within the artery wall is a key contributor to residual risk for heart attack and stroke, contributing to both vulnerable plaque formation and to plaque rupture.
Inflammation can be easily measured with advanced testing to more fully assess cardiometabolic risk. Monitoring a patient’s inflammatory status may help you to uncover hidden risks from early to advanced stages of cardiovascular disease. With deeper insights, you can take further action to help reduce your patients’ cardiovascular risk. Cardio IQ® inflammatory marker testing provides a comprehensive biomarker profile, spanning markers linked to lifestyle factors (F2-IsoPs, OxLDL), indicators of metabolic or cardiovascular disease risk (ADMA/SDMA, microalbumin, hsCRP), and markers associated with vulnerable plaque formation and heightened risk of adverse events (Lp-PLA2, MPO).
Key takeaways
- Through its Cleveland HeartLab Cardiometabolic Center of Excellence, Quest Diagnostics now offers expanded, unique inflammation testing that provides additional and complementary insight into cardiovascular risk beyond lipid testing alone.
- Cardio IQ inflammation testing consists of easy-to-perform blood and urine biomarkers that identify inflammatory risks across the disease spectrum.